GSA Capital Partners LLP Has $777,000 Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK)

GSA Capital Partners LLP decreased its stake in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 20.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 31,475 shares of the biotechnology company’s stock after selling 8,087 shares during the period. GSA Capital Partners LLP owned 0.21% of Anika Therapeutics worth $777,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in ANIK. Vanguard Group Inc. grew its holdings in Anika Therapeutics by 1.3% during the first quarter. Vanguard Group Inc. now owns 773,702 shares of the biotechnology company’s stock valued at $19,652,000 after purchasing an additional 9,657 shares during the last quarter. Renaissance Technologies LLC grew its stake in Anika Therapeutics by 6.9% in the 2nd quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after buying an additional 38,412 shares during the last quarter. Acadian Asset Management LLC grew its stake in Anika Therapeutics by 5.1% in the 2nd quarter. Acadian Asset Management LLC now owns 442,944 shares of the biotechnology company’s stock valued at $11,217,000 after buying an additional 21,517 shares during the last quarter. Meros Investment Management LP raised its holdings in Anika Therapeutics by 25.0% in the 2nd quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock worth $5,388,000 after acquiring an additional 42,587 shares during the period. Finally, Stonepine Capital Management LLC lifted its position in Anika Therapeutics by 171.4% during the 2nd quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company’s stock worth $4,190,000 after acquiring an additional 104,448 shares during the last quarter. 91.53% of the stock is owned by institutional investors.

Anika Therapeutics Stock Up 1.5 %

Shares of ANIK opened at $17.25 on Monday. The company has a 50-day simple moving average of $22.96 and a 200-day simple moving average of $25.03. Anika Therapeutics, Inc. has a 52 week low of $16.00 and a 52 week high of $29.11.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on ANIK shares. Barrington Research dropped their price objective on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. StockNews.com lowered Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, November 4th.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.